ABOUT
About This Ipamorelin Digest
What this site is, what it is not, and the editorial standard behind every cited claim.
What this site is
Pharmacy Ipamorelin is an independent editorial project that publishes plain-English summaries of the peer-reviewed research literature on ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science, read deliberately through one lens: pharmacokinetics — how ipamorelin enters, moves through, and leaves the body, and the single growth-hormone pulse that follows.
About the name — and the word 'pharmacy'
The word 'pharmacy' in this domain is editorial framing, not a description of any service. This site is not a pharmacy. It stocks nothing, dispenses nothing, fills no orders, and is not a place to obtain ipamorelin. Ipamorelin is not an approved or stocked pharmacy medication anywhere [2]. We chose the kinetics lens because a pharmacy's core competence — knowing exactly how a substance behaves once it is in the body — is precisely what the published ipamorelin record can speak to: half-life, clearance, the time-course of the GH response [1]. That is the position this publisher occupies relative to the literature, and nothing more.
Is ipamorelin fda approved
No. Ipamorelin is not FDA approved as a drug for any indication, and it has never been approved by any regulator anywhere [2]. It was investigated for postoperative ileus (NCT00672074), but that Phase 2 trial missed its primary endpoint and no further development followed [2]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug-substances list and reviewed it at an October 2024 Pharmacy Compounding Advisory Committee meeting, restricting compounding-pharmacy access. It is marketed only as a research chemical, and it is banned in sport at all times under the WADA Prohibited List (category S2) [2].
Our editorial standard
Every quantitative claim on this site — every dose, half-life, percentage, and p-value — maps to a numbered citation on the references page, drawn from PubMed, peer-reviewed journals, and ClinicalTrials.gov. Where the human evidence is thin, we say so plainly rather than dressing up rodent data as proof. Where effects are reported only by the research-use community, we label them anecdotal and never attach a dose. We do not name drug brands, we do not recommend a human dose, and we do not tell anyone what to do. The aim is a faithful, readable map of what the studies actually measured.